Maria Sharapova, former world number one tennis player, failed a drug test for Meldonium on January 26, 2016. Meldonium (also known as Mildronate) is manufactured in Latvia and used in the treatment of certain heart conditions. It works by dilating blood vessels and increasing blood flow, which in turn improves exercise capacity, physical and mental endurance, and also brain function.
Meldonium was on the World Anti-Doping Agency’s (WADA) list of drugs being monitored until September 2015, when it was added to the list of banned substances, effective January 1, 2016.
Maria Sharapova had been taking Meldonium since 2006. Her family doctor had prescribed it for her irregular EKGs, magnesium deficiency, and a family history of diabetes. Sharapova claims she was unaware Meldonium had been added to the WADA list of banned substances until receipt of a letter from the International Tennis Federation informing her of a failed drug test during the 2016 Australian Open.
CAS registry number (Chemical Abstracts Service)
Treatment of cardiac disorders
Inhibitor of carnitine synthesis
- Meldonium (Latin)
- Meldonium (German)
- Meldonium (French)
- Meldonio (Spanish)
- Mildronate (IS)
- Meldonium Olainfarm
UP Minskintercaps, Georgia
Grindeks, Georgia; Sanitas, Georgia
- Mildronat Grindeks
Makis Pharma, Russian Federation
Grindeks, Lithuania; Grindex, Russian Federation
|IUPAC||International Union of Pure and Applied Chemistry|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|WHO||World Health Organization|
Click for further information on drug naming conventions and International Nonproprietary Names.